THX Pharma (ALTHX)

Executive Summary

THX Pharma (Theranexus) is a French clinical-stage biopharmaceutical company spun out from the French Alternative Energies and Atomic Energy Commission (CEA), focused on developing advanced therapies for rare neurological disorders. Leveraging a proprietary platform for drug candidate identification and characterization, the company’s lead program targets Batten disease, a devastating lysosomal storage disorder with no approved therapies. The platform's ability to repurpose and optimize small molecules for central nervous system (CNS) indications positions THX Pharma as a unique player in the rare disease space. The company is publicly traded on Euronext Growth under ticker ALTHX, allowing investors access to its pipeline progress and potential partnerships. THX Pharma’s near-term value hinges on clinical data from its Batten disease program, which is expected to read out in mid-2026. Positive results could validate the platform and unlock significant commercial opportunities, given the high unmet need and orphan drug designation. Beyond Batten, the platform has potential to address other rare neurological conditions, providing a pipeline-in-a-product strategy. However, as a small-cap biotech, the company faces typical risks of clinical development and financing. Upcoming catalysts, including data readouts and partnership discussions, will be critical for de-risking the story and driving shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Data Readout for Batten Disease Program40% success
• H2 2026Potential Strategic Partnership for Platform Technology30% success
• 2027IND Filing for New Neurological Indication50% success